The PF-10 scores improved significantly more in men treated with testosterone than in men treated with placebo among men whose baseline 6MWS was ≥1.2 m/sec (treatment effect 4.9, 95% CI (2.2, 7.7) PFigure 3). Adherence to assigned treatment in men enrolled in the PFT, assessed by weighing the returned bottles and comparing it to the expected weight based on the prescribed dose, was high in both the testosterone and placebo groups (means 97% and 92%), respectively, with fewer than 5% of men with compliance135%). The primary analysis was performed using random effects models for longitudinal data, which included visit time as a categorical variable and a single main effect for treatment, and included balancing factors and baseline value of the 6-minute walking distance as fixed effect covariates. Our expectation was that men who walked more slowly and perceived mobility problems would be more likely to benefit from testosterone treatment than men who were functioning at a higher level.
While this trial aims to demonstrate that testosterone safely and effectively promotes gains in muscle strength and physical function in a group of older men with mobility limitations, the design has taken into consideration many of the conceptual and methodological hurdles facing clinical trials of anabolic, function promoting therapies. The TOM study will target older men with low testosterone levels who meet an operational definition of mobility limitations that includes self-reported and objectively demonstrated limitations in physical function and mobility. Testosterone treatment of older men with mobility limitation who have clearly low testosterone levels consistently improves self-reported mobility but has a modest effect on walking speed. Testosterone also likely improved 6MWD but the treatment effect was modest and appeared to be related to baseline gait speed, the self-reported mobility limitation, and changes in testosterone and hemoglobin levels. Testosterone’s effect on mobility measures in older men with low testosterone were related to baseline gait speed and self-reported mobility limitation, and changes in testosterone and hemoglobin levels.
The PFT is the largest controlled trial of testosterone’s effects on physical function and mobility in older men. It is possible that functional exercise training may augment the translation of testosterone-induced muscle mass and strength gains into functional improvements, as exercise training has been reported to augment the anabolic effects of testosterone (30). TTrials is one of the largest testosterone trials to be conducted to-date which enrolled older men with unequivocally low testosterone levels, measured using liquid chromatography tandem mass spectrometry assay certified by the Center for Disease Control’s Hormone Standardization Program for Testosterone (HoST). The improvement in self-reported mobility and function, measured by the PF-10 and the PGIC, was observed in all men treated with testosterone, regardless of the baseline walk speed, although the specific effect on 6MWD was greater in men with higher gait speed. Comparison of change in 6-minute walking distance and PF10 scores in men enrolled in the Physical Function Trial and men not enrolled in the physical function trial.
The observation that testosterone administration increases skeletal muscle mass and maximal voluntary muscle strength (1–9) has led to considerable pharmaceutical interest in applying testosterone as an anabolic therapy to improve physical function and to reduce the burden of disability in older men with mobility limitation. In this initial trial, we are confident that testosterone therapy will increase muscle mass and strength (primary outcome) and propose that this will translate into improvements in physical function (secondary outcomes). In contrast to recent trials of replacement therapy in older men that achieved only marginal increases in testosterone levels, this study aims to restore testosterone to the mid- to high-normal range. Subjects will perform laboratory-based measures of muscle performance, physical function and physical activity at baseline and following 3 and 6 months of treatment. The secondary aim of this study is to test whether testosterone administration mediates improvements in self-reported as well as performance-based measures of physical function, self-reported disability and habitual physical activity. A total of 252 community dwelling individuals aged 65 and older with low testosterone levels and self-reported limitations in mobility and short physical performance battery (SPPB) score between 4 and 9 will be randomized to receive either placebo or testosterone therapy for 6 months. Unlike previous trials, which often used surrogate endpoints such as lean body mass and muscle performance measures, the TTrials included physical function outcomes that were deemed patient-important and of public health significance.
An Institute of Medicine panel concluded that there was insufficient evidence of a beneficial effect of testosterone replacement on physical function and mobility in older men with functional limitations (16). Testosterone-treated men with baseline walking speed ≥1.2 m/sec experienced significantly greater improvements in 6MWD and in PF10 than placebo-treated men. It’s also important to consider the effects of oestrogen, progesterone and testosterone on muscles, which will affect the pelvic floor – and therefore can have an effect on bladder control too. Lower levels of testosterone can lead to decreased muscle tone and further instability of hypermobile joints. Understanding the impact of testosterone on joints/connective tissues/muscle may provide insights for improving the management of hypermobility disorders in everyone. However, testosterone replacement therapy (TRT) can help restore testosterone levels and improve joint health. Low testosterone levels can contribute to joint pain, stiffness, and limited range of motion.
Some individuals may notice positive changes within a few weeks, while others may take several months. The timeframe for experiencing improvements in joint health and mobility with TRT can vary from person to person. While TRT can be beneficial for joint health, it is essential to consider potential risks and side effects. This can alleviate joint pain, stiffness, and enhance overall mobility. Without sufficient testosterone, cartilage may become less effective in cushioning the joints, leading to discomfort and limited range of motion.
The Patient Global Impression of Change scores indicated a significantly positive impact of testosterone on participant’s perception of improvement in his walking ability overall and separately in men enrolled and not enrolled in the PFT. Thus, testosterone should probably not be started specifically to improve physical function, but men who are treated with testosterone for other reasons may experience some improvement in physical function. The overall treatment effect on 6MWD was small, but not dissimilar from that of a physical activity intervention in older adults with mobility limitation (29). Additionally, we included a patient global impression of change to corroborate whether the patients perceived their walking speed to have improved. We asked men at each visit whether they perceived any changes in their walking ability since the start of the trial using a 7-point scale ranging from "much worse" to "much better" (PGIC).

Gender: Female

Social links